| Dr Randy Scott Lovelace, MD | |
|
1225 E Weisgarber Rd Ste 200, Knoxville, TN 37909-2675 | |
| (865) 584-4747 | |
| (865) 584-1363 |
| Full Name | Dr Randy Scott Lovelace |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 1225 E Weisgarber Rd Ste 200, Knoxville, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154393619 | NPI | - | NPPES |
| Q020292 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | MD37328 (Tennessee) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 01080443A (Indiana) | Primary |
| Entity Name | Summit Medical Group, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659090298 PECOS PAC ID: 2860396330 Enrollment ID: O20031125000793 |
News Archive
According to a new United Nations report the use of stimulant drugs of abuse like amphetamine, ecstasy and meth is increasing worldwide. The report adds that the growing trade in these illegal drugs and the high profits they bring to criminals are posing an increasing threat to health and security.
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company in the field of epigenetics, today announced that it has been awarded a research grant in collaboration with the University of Pittsburgh School of Medicine from the Cystic Fibrosis Foundation to explore the potential use of BET bromodomain inhibitors for the control of inflammation in cystic fibrosis.
Eli Lilly and Company announced today that its chemotherapy ALIMTA® (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE).
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has initiated patient dosing in a Phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) infection. ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication. The drug candidate was discovered and is being advanced by Achillion.
The Department of Health and Human Services has selected the Hospital of the University of Pennsylvania (HUP) as one of five hospitals that will take part in a nationwide initiative designed to train more nurses at a higher level.
› Verified 1 days ago
| Entity Name | Hospital Medicine Services Of Tennessee Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528433802 PECOS PAC ID: 9234432881 Enrollment ID: O20160114002673 |
News Archive
According to a new United Nations report the use of stimulant drugs of abuse like amphetamine, ecstasy and meth is increasing worldwide. The report adds that the growing trade in these illegal drugs and the high profits they bring to criminals are posing an increasing threat to health and security.
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company in the field of epigenetics, today announced that it has been awarded a research grant in collaboration with the University of Pittsburgh School of Medicine from the Cystic Fibrosis Foundation to explore the potential use of BET bromodomain inhibitors for the control of inflammation in cystic fibrosis.
Eli Lilly and Company announced today that its chemotherapy ALIMTA® (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE).
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has initiated patient dosing in a Phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) infection. ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication. The drug candidate was discovered and is being advanced by Achillion.
The Department of Health and Human Services has selected the Hospital of the University of Pennsylvania (HUP) as one of five hospitals that will take part in a nationwide initiative designed to train more nurses at a higher level.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Randy Scott Lovelace, MD 1225 E Weisgarber Rd Ste 200, Knoxville, TN 37909-2675 Ph: (865) 584-4747 | Dr Randy Scott Lovelace, MD 1225 E Weisgarber Rd Ste 200, Knoxville, TN 37909-2675 Ph: (865) 584-4747 |
News Archive
According to a new United Nations report the use of stimulant drugs of abuse like amphetamine, ecstasy and meth is increasing worldwide. The report adds that the growing trade in these illegal drugs and the high profits they bring to criminals are posing an increasing threat to health and security.
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company in the field of epigenetics, today announced that it has been awarded a research grant in collaboration with the University of Pittsburgh School of Medicine from the Cystic Fibrosis Foundation to explore the potential use of BET bromodomain inhibitors for the control of inflammation in cystic fibrosis.
Eli Lilly and Company announced today that its chemotherapy ALIMTA® (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE).
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has initiated patient dosing in a Phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) infection. ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication. The drug candidate was discovered and is being advanced by Achillion.
The Department of Health and Human Services has selected the Hospital of the University of Pennsylvania (HUP) as one of five hospitals that will take part in a nationwide initiative designed to train more nurses at a higher level.
› Verified 1 days ago
Corey Cudzilo, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2240 Sutherland Ave, Suite 103, Knoxville, TN 37919 Phone: 865-588-8831 Fax: 865-588-8841 | |
Dr. Joshua Weber Todd, M.D. Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 1819 W Clinch Ave, Suite 108, Knoxville, TN 37916 Phone: 865-546-5111 Fax: 865-541-4018 | |
Rasmi Ajit, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9330 Park West Blvd Ste 402, Knoxville, TN 37923 Phone: 865-690-3003 Fax: 865-374-2143 | |
Dr. Spencer Pugh, M.D. Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 1924 Alcoa Hwy, Department Of Medicine U-114 Gsm, Utmck, Knoxville, TN 37920 Phone: 865-305-9340 Fax: 865-305-9144 | |
Saji Eapen, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1415 Old Weisgarber Rd, Suite 200, Knoxville, TN 37909 Phone: 865-934-5800 Fax: 865-934-5801 | |
Jeffrey W Robinson, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6600 Nightingale Ln, Knoxville, TN 37909 Phone: 865-632-5885 | |
Dr. Mark D Anderson, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1928 Alcoa Hwy, B100, Knoxville, TN 37920 Phone: 865-544-6570 Fax: 865-544-6576 |